IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes
Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.
The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.
Veeva Systems (NYSE:VEEV) e IQVIA (NYSE:IQV) hanno annunciato partnership globali complete nei settori clinico e commerciale, risolvendo al contempo tutte le controversie legali pendenti. L'accordo pluriennale consente un'integrazione senza soluzione di continuit脿 di software, dati, tecnologie e servizi di entrambe le aziende.
La collaborazione commerciale prevede accordi su dati master e accesso a terze parti, permettendo l'utilizzo reciproco dei dati su piattaforme quali Veeva Network, Veeva Nitro e Veeva AI. IQVIA si 猫 inoltre unita a diversi programmi partner di Veeva per supportare le integrazioni per i clienti. Sul fronte clinico, la partecipazione di IQVIA al programma CRO Clinical Data Partner di Veeva agevoler脿 l'esecuzione di studi clinici utilizzando i prodotti software di Veeva, in particolare per le implementazioni di EDC (Electronic Data Capture).
Veeva Systems (NYSE:VEEV) e IQVIA (NYSE:IQV) han anunciado alianzas globales integrales en los 谩mbitos cl铆nico y comercial, adem谩s de resolver todas las disputas legales pendientes. El acuerdo a largo plazo permite la integraci贸n fluida de los software, datos, tecnolog铆as y servicios de ambas compa帽铆as.
La asociaci贸n comercial establece acuerdos de datos maestros y de acceso a terceros, permitiendo el uso mutuo de datos en plataformas como Veeva Network, Veeva Nitro y Veeva AI. IQVIA se ha incorporado a varios programas de socios de Veeva para apoyar integraciones con clientes. En el 谩mbito cl铆nico, la participaci贸n de IQVIA en el programa CRO Clinical Data Partner de Veeva facilitar谩 la ejecuci贸n de ensayos cl铆nicos utilizando los productos de software de Veeva, especialmente en implementaciones de EDC (Electronic Data Capture).
Veeva Systems (NYSE:VEEV)鞕赌 IQVIA (NYSE:IQV)臧� 鞛勳儊 氚� 靸侅梾 攵勳暭鞐愳劀 韽磩鞝侅澑 旮�搿滊矊 韺岉姼雱堨嫮鞚� 氚滍憸頃橁碃 氇摖 瓿勲 欷戩澑 氩曥爜 攵勳焷鞚� 頃搓舶頄堨姷雼堧嫟. 鞛リ赴 瓿勳暯鞚� 韱淀暣 鞏戩偓鞚� 靻岉攧韸胳洦鞏�, 雿办澊韯�, 旮办垹 氚� 靹滊箘鞀り皜 鞗愴櫆頃橁矊 韱淀暕霅╇媹雼�.
靸侅梾鞝� 韺岉姼雱堨嫮鞚� 毵堨姢韯� 雿办澊韯� 氚� 鞝�3鞛� 鞝戧芳 瓿勳暯鞚� 毵堧牗頃橃棳 Veeva Network, Veeva Nitro, Veeva AI 霌� 頂岆灚韽� 鞝勲皹鞐愳劀 雿办澊韯� 靸來樃 靷毄鞚� 項堨毄頃╇媹雼�. IQVIA電� 瓿犼皾 韱淀暕鞚� 歆�鞗愴晿旮� 鞙勴暣 鞐煬 Veeva 韺岉姼雱� 頂勲攴鸽灗鞐� 彀胳棳頄堨姷雼堧嫟. 鞛勳儊 攵勳暭鞐愳劀電� IQVIA臧� Veeva鞚� CRO Clinical Data Partner 頂勲攴鸽灗鞐� 彀胳棳頃溂搿滌崹 韸鬼瀳 EDC (Electronic Data Capture) 甑槃鞐愳劀 Veeva 靻岉攧韸胳洦鞏� 鞝滍拡鞚� 頇滌毄頃� 鞛勳儊鞁滍棙 靾橅枆鞚� 鞗愴櫆頃挫 瓴冹瀰雼堧嫟.
Veeva Systems (NYSE:VEEV) et IQVIA (NYSE:IQV) ont annonc茅 des partenariats mondiaux complets dans les domaines clinique et commercial, tout en r茅glant l'ensemble des litiges en cours. L'accord 脿 long terme permet l'int茅gration fluide des logiciels, donn茅es, technologies et services des deux entreprises.
Le partenariat commercial 茅tablit des accords de donn茅es ma卯tres et d'acc猫s tiers, autorisant l'utilisation r茅ciproque des donn茅es sur des plateformes telles que Veeva Network, Veeva Nitro et Veeva AI. IQVIA a rejoint plusieurs programmes partenaires de Veeva pour soutenir les int茅grations clients. Dans le domaine clinique, la participation d'IQVIA au programme CRO Clinical Data Partner de Veeva facilitera l'ex茅cution des essais cliniques en utilisant les produits logiciels de Veeva, en particulier pour les mises en 艙uvre d'EDC (Electronic Data Capture).
Veeva Systems (NYSE:VEEV) und IQVIA (NYSE:IQV) haben umfassende globale Partnerschaften in den klinischen und kommerziellen Bereichen angek眉ndigt und gleichzeitig alle anh盲ngigen Rechtsstreitigkeiten beigelegt. Die langfristige Vereinbarung erm枚glicht eine nahtlose Integration der Software, Daten, Technologien und Dienstleistungen beider Unternehmen.
Die kommerzielle Partnerschaft umfasst Master-Daten- und Drittzugangsvereinbarungen, die eine gegenseitige Datennutzung 眉ber Plattformen wie Veeva Network, Veeva Nitro und Veeva AI erlauben. IQVIA ist mehreren Veeva-Partnerprogrammen beigetreten, um Kundenintegrationen zu unterst眉tzen. Im klinischen Bereich wird IQVIAs Teilnahme am Veeva CRO Clinical Data Partner-Programm die Durchf眉hrung klinischer Studien mit den Softwareprodukten von Veeva erleichtern, insbesondere bei Implementierungen von EDC (Electronic Data Capture).
- None.
- None.
Insights
IQVIA-Veeva partnership resolves legal disputes and creates significant value through integrated clinical/commercial solutions, greatly benefiting both companies' market positions.
This partnership agreement between IQVIA and Veeva represents a significant strategic development for both companies, ending what had been a contentious relationship marked by legal disputes. The resolution creates substantial operational and commercial value by enabling seamless integration between Veeva's software platforms and IQVIA's data and services.
The partnership spans two critical domains: commercial operations and clinical trials. On the commercial side, the master data and third-party access agreements allow for crucial data interoperability 鈥� IQVIA's industry-leading data can now be used within Veeva's Network (for master data management), Nitro (analytics), and AI applications. Simultaneously, Veeva's data becomes available within IQVIA's commercial ecosystem.
On the clinical side, IQVIA joining Veeva's CRO Clinical Data Partner program enables the use of Veeva's Clinical Suite for trial execution, including the critical EDC (Electronic Data Capture) system. This integration will accelerate database builds, study locks, and data delivery 鈥� addressing major pain points in clinical development timelines.
The partnership eliminates significant friction for life sciences companies that previously had to navigate complex technical and legal barriers when attempting to use both companies' solutions together. By joining each other's partner programs and establishing master agreements, they've created a streamlined process for third-party access approvals, addressing a major operational headache for their clients.
For Veeva, this removes a competitive obstacle and expands their software platforms' utility. For IQVIA, it opens access to a significant software customer base and enhances the value proposition of their data and services. The resolution of legal disputes also eliminates uncertainty and potential financial liabilities for both companies.
Global partnerships to help customers improve clinical and commercial efficiency and effectiveness
The global partnerships make it easy for customers to work with IQVIA and Veeva in key areas including:
- Commercial: The companies have established master data and software third-party access (TPA) agreements that allow IQVIA or Veeva data to be used with each other's software or services in customer instances, including the use of IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. In addition to the use of Veeva data in IQVIA's commercial products and services, IQVIA has also joined the Veeva Technology, AI, and Services Partner Programs to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI, and IQVIA Commercial Orchestration offerings. With these partnerships and overall master agreements in place, customers also benefit from a fast, easy process to get TPAs for projects.
- Clinical: IQVIA has joined Veeva's CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. With this partnership, customers will benefit from IQVIA's clinical data management, clinical technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery.听
"We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall," said Veeva founder and CEO Peter Gassner. "I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers."
"IQVIA and Veeva's partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients," said Ari Bousbib, chairman and CEO of IQVIA. "This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients."
For more information visit 听on iqvia.com or on veeva.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence鈩� to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI庐, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit听.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a , Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit .
Veeva Forward-looking Statements
This release contains forward-looking statements regarding the expected results and benefits from Veeva's partnerships with IQVIA. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements.
Contacts: | |
Maria Scurry Veeva Media Relations 781-366-7617 听 Gunnar Hansen Veeva Investor Relations 267-460-5839 听 听 听 | Alissa Maupin IQVIA Media Relations 919-923-6785 听 Kerri Joseph IQVIA Investor Relations 973-541-3558 听 听 听 |
听
View original content to download multimedia:
SOURCE Veeva Systems
FAQ
What is the new partnership between Veeva Systems and IQVIA?
How does the VEEV-IQVIA partnership benefit customers?
What specific Veeva products are included in the IQVIA partnership?
What programs has IQVIA joined as part of the Veeva partnership?
How will the Veeva-IQVIA partnership affect clinical trials?
